Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- Registration Number
- NCT00004151
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery.
- Detailed Description
OBJECTIVES: I. Determine the effect of acridine carboxamide on objective response, response rate, and duration of response in patients with unresectable, locally advanced, progressive or metastatic non-small cell lung cancer. II. Determine the toxicities and pharmacokinetics of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients receive acridine carboxamide IV over 24 hours for 5 days. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks until disease progression or commencement of another treatment.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Istituto Nazionale per lo Studio e la Cura dei Tumori
🇮🇹Naples, Italy
Haemato-Onkologische Praxis und Tagesklinik
🇩🇪Munich, Germany
CHU de la Timone
🇫🇷Marseille, France
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Kaiser Franz Josef Hospital
🇦🇹Vienna, Austria
Rigshospitalet
🇩🇰Copenhagen, Denmark
Centre de Lute Contre le Cancer,Georges-Francois Leclerc
🇫🇷Dijon, France
Istituti Fisioterapici Ospitalieri - Roma
🇮🇹Rome, Italy